{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:58:08Z","timestamp":1783702688842,"version":"3.55.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:p>This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.<\/jats:p>","DOI":"10.1001\/jamadermatol.2023.5036","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T16:02:13Z","timestamp":1703088133000},"page":"226","source":"Crossref","is-referenced-by-count":6,"title":["Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022"],"prefix":"10.1001","volume":"160","author":[{"given":"Samir","family":"Kamat","sequence":"first","affiliation":[{"name":"Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"dld230026r1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/archdermatol.2011.100","article-title":"New drugs and new molecular entities in dermatology.","volume":"147","author":"Eaglstein","year":"2011","journal-title":"Arch Dermatol"},{"issue":"7","key":"dld230026r2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/jamadermatol.2015.0231","article-title":"Topical drug innovation from 2000 through 2014.","volume":"151","author":"Walter","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"5","key":"dld230026r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1096","article-title":"Approvals and timing of new formulations of novel drugs approved by the US Food and Drug Administration between 1995 and 2010 and followed through 2021.","volume":"3","author":"Gupta","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"15","key":"dld230026r4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jama.2023.4034","article-title":"Added therapeutic benefit of top-selling brand-name drugs in Medicare.","volume":"329","author":"Egilman","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"dld230026r5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"dld230026r6","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.12788\/cutis","article-title":"Active comparator trial designs used to promote development of innovative new medications.","volume":"106","author":"Barbieri","year":"2020","journal-title":"Cutis"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2812731\/jamadermatology_kamat_2023_ld_230026_1707346956.76827.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T16:02:15Z","timestamp":1708531335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2812731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5036","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}